Christoph Rochlitz

9.0k total citations · 4 hit papers
137 papers, 6.5k citations indexed

About

Christoph Rochlitz is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Christoph Rochlitz has authored 137 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 40 papers in Molecular Biology and 32 papers in Cancer Research. Recurrent topics in Christoph Rochlitz's work include Cancer Treatment and Pharmacology (21 papers), HER2/EGFR in Cancer Research (16 papers) and Breast Cancer Treatment Studies (15 papers). Christoph Rochlitz is often cited by papers focused on Cancer Treatment and Pharmacology (21 papers), HER2/EGFR in Cancer Research (16 papers) and Breast Cancer Treatment Studies (15 papers). Christoph Rochlitz collaborates with scholars based in Switzerland, Germany and United States. Christoph Rochlitz's co-authors include Richard Herrmann, Marcus Vetter, Francesc Castro-Giner, Nicola Aceto, William P. Weber, Ilona Krol, Viola Heinzelmann‐Schwarz, Christian Kurzeder, Ramona Scherrer and Barbara M. Szczerba and has published in prestigious journals such as Nature, Cell and Nature Genetics.

In The Last Decade

Christoph Rochlitz

135 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neutrophils escort circulating tumour cells to enable cell cycle progression

2019 886 citations Barbara M. Szczerba, Francesc Castro-Giner et al. profile →
Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding

2019 608 citations Sofia Gkountela, Francesc Castro-Giner et al. profile →
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [⁹⁰Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

2011 452 citations Philippe Brunner, Nicolas Marincek et al. profile →
The metastatic spread of breast cancer accelerates during sleep

2022 180 citations Zoi Diamantopoulou, Francesc Castro-Giner et al. profile →

Peers

Countries citing papers authored by Christoph Rochlitz

Since Specialization

Citations

This map shows the geographic impact of Christoph Rochlitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christoph Rochlitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christoph Rochlitz more than expected).

Fields of papers citing papers by Christoph Rochlitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christoph Rochlitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christoph Rochlitz. The network helps show where Christoph Rochlitz may publish in the future.

Co-authorship network of co-authors of Christoph Rochlitz

This figure shows the co-authorship network connecting the top 25 collaborators of Christoph Rochlitz. A scholar is included among the top collaborators of Christoph Rochlitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christoph Rochlitz. Christoph Rochlitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Group-based body psychotherapy improves appreciation of body awareness in post-treatment cancer patients: A non-randomized clinical trial 2023 ·Frontiers in Psychology ·(unknown), Cornelia Meffert, Viviane Hess, Christoph Rochlitz, Miklos Pless, Sabina Hunziker, (unknown), Ulfried Geuter, Gunther Meinlschmidt, Rainer Schaefert	2
2	Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14] 2022 ·Journal of Geriatric Oncology ·(unknown), Andreas Mueller, Qiyu Li, Beat Thuerlimann, Karin Ribi, Stefan Gerber, Roger von Moos, Mathias K. Fehr, Christoph Rochlitz, Khalil Zaman, Stefan Aebi, (unknown), (unknown), (unknown), (unknown), A Schreiber, Clemens B. Caspar, Andreas Trojan, Rosaria Condorelli, Thomas Ruhstaller	1
3	An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression 2021 ·Cancer Research ·Manuel C. Scheidmann, Francesc Castro-Giner, Karin Strittmatter, Ilona Krol, Aino Paasinen-Sohns, Ramona Scherrer, Cinzia Donato, Sofia Gkountela, Barbara M. Szczerba, Zoi Diamantopoulou, Simone Muenst, Tatjana Vlajnic, Leo Kunz, Marcus Vetter, Christoph Rochlitz, Verdon Taylor, Claudio Giachino, Timm Schroeder, Randall J. Platt, Nicola Aceto	18
4	268P Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14] 2021 ·Annals of Oncology ·Andreas Wicki, Christoph Mamot, (unknown), (unknown), (unknown), (unknown), (unknown), Khalil Zaman, Roger von Moos, Konstantin J. Dedes, Urban Novak, Alexandre Bodmer, Reto Ritschard, Ellen C. Obermann, Christoph Ackermann, (unknown), (unknown), Clemens B. Caspar, Christoph Rochlitz, (unknown)	4
5	A clinical trial of group-based body psychotherapy to improve bodily disturbances in post-treatment cancer patients in combination with randomized controlled smartphone-triggered bodily interventions (KPTK): study protocol 2019 ·BMC Psychology ·(unknown), Cornelia Meffert, Viviane Hess, Christoph Rochlitz, Miklos Pless, Sabina Hunziker, (unknown), Ulfried Geuter, Gunther Meinlschmidt, Rainer Schaefert	2
6	Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data 2019 ·BMC Cancer ·Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, C. Oehlschlegel, Olivia Pagani, Bernhard C. Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman, Thomas Ruhstaller	7
7	Focusing on cancer patients' intentions to use psychooncological support: A longitudinal, mixed‐methods study 2018 ·Psycho-Oncology ·Theresa Tondorf, (unknown), Sacha I. Rothschild, Michael Koller, Christoph Rochlitz, Alexander Kiss, Rainer Schaefert, Gunther Meinlschmidt, Sabina Hunziker, Diana Zwahlen	49
8	Fertility Preservation in Young Female Cancer Patients: Development and Pilot Testing of an Online Decision Aid 2017 ·Journal of Adolescent and Young Adult Oncology ·(unknown), Corinne Urech, Christoph Rochlitz, (unknown), Rebecca Moffat, Ruth Stiller, (unknown), Michael von Wolff, Frank Nawroth, (unknown), Ariane Germeyer, Sebastian Findeklee, Sibil Tschudin	31
9	Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10) 2017 ·BMC Cancer ·Bernhard C. Pestalozzi, Christoph Tausch, Konstantin J. Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, (unknown), Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, (unknown), Bettina Seifert, (unknown), (unknown), (unknown), Christoph Rageth, Stefan Aebi	10
10	Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy 2015 ·Journal of drug targeting ·Annette Orleth, Christoph Mamot, Christoph Rochlitz, Reto Ritschard, Kari Alitalo, Gerhard Christofori, Andreas Wicki	18
11	Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors 2014 ·EJNMMI Research ·Andreas Wicki, Damian Wild, (unknown), Rosalba Mansi, Annette Orleth, Jean–Claude Reubi, Christoph Rochlitz, Christoph Mamot, Helmut R. Mäcke, Gerhard Christofori	4
12	Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study 2013 ·Journal of Translational Medicine ·Nicolas Marincek, (unknown), Philippe Brunner, Christian Schindler, Michael Koller, Christoph Rochlitz, Jan Müller‐Brand, Helmut R. Maëcke, Matthias Briel, Martin A. Walter	21
13	Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours 2013 ·European Journal of Nuclear Medicine and Molecular Imaging ·(unknown), (unknown), Nicolas Marincek, Philippe Brunner, Michael Koller, (unknown), Helmut R. Maëcke, Jan Müller‐Brand, Christoph Rochlitz, Matthias Briel, Christian Schindler, Martin A. Walter	61
14	Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth 2011 ·Clinical Cancer Research ·Andreas Wicki, Christoph Rochlitz, Annette Orleth, Reto Ritschard, Imke Albrecht, Richard Herrmann, Gerhard Christofori, Christoph Mamot	77
15	A new approach in breast cancer with non-inflammatory skin involvement 2006 ·Acta Oncologica ·Uwe Güth, Edward Wight, Andreas Schötzau, Igor Langer, Holger Dieterich, Christoph Rochlitz, (unknown), Wolfgang Holzgreve, Gad Singer	14
16	Current Concepts of Treatment Strategies in Advanced or Recurrent Ovarian Cancer 2005 ·Oncology ·Marc Salzberg, Beat Thürlimann, (unknown), Daniel Fink, Christoph Rochlitz, Roger von Moos, Hans-Jörg Senn	58
17	Breast carcinoma with noninflammatory skin involvement (T4b) 2005 ·Cancer ·Uwe Güth, Edward Wight, Andreas Schötzau, Igor Langer, Holger Dieterich, Christoph Rochlitz, (unknown), Wolfgang Holzgreve, Gad Singer	15
18	STRAP Is a Strong Predictive Marker of Adjuvant Chemotherapy Benefit in Colorectal Cancer 2004 ·Neoplasia ·Martin Buess, Luigi Terracciano, (unknown), Pierluigi Ballabeni, Jean‐Louis Boulay, U Laffer, U Metzger, Richard Herrmann, Christoph Rochlitz	25
19	Amplification of SKI Is a Prognostic Marker in Early Colorectal Cancer 2004 ·Neoplasia ·Martin Buess, Luigi Terracciano, (unknown), Pierluigi Ballabeni, Jean‐Louis Boulay, U Laffer, U Metzger, Richard Herrmann, Christoph Rochlitz	54
20	Use of the Polymerase Chain Reaction Technique to Create Base-Specific ras Oncogene Mutations 1988 ·DNA ·Christoph Rochlitz, G K Scott, James M. Dodson, Chris Benz	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact